arrow
M

Michel W.J.M. Wouters

dutch institute for clinical auditing
H指数:64
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early Cessation of Adjuvant Anti-PD-1 Therapy in Stage III and IV Melanoma

III期和IV期黑色素瘤中辅助抗PD-1疗法的早期终止

2026-09-100
OAAI
Advancing learning health care systems with best practice meetings: a mixed-methods study with insights from the Dutch Institute for Clinical Auditing

通过最佳实践会议推动学习型医疗保健系统:一项结合荷兰临床审核研究所见解的混合方法研究

2026-08-080
OAAI
Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy

不可切除的转移性黑色素瘤的治疗策略及其反应与生存情况

2026-06-210
OA
Attitudes and practices regarding dosing interval extension of biologics in severe asthma: a nationwide survey and real-world data from the Dutch RAPSODI registry

关于生物制剂在重症哮喘中延长给药间隔的态度与实践:一项全国性调查和来自荷兰RAPSODI登记研究的真实世界数据

2026-04-030
OAAI
Predictive value of [18F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: real world data from the largest melanoma centres in the Netherlands

[18F]FDG PET/CT的预测价值及新辅助帕博利珠单抗治疗后哨兵淋巴结反应:来自荷兰最大黑色素瘤中心的真实世界数据

2026-03-240
OAAI
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

黑色素瘤的新辅助治疗ipilimumab联合nivolumab: 来自2期PRADO试验的5年生存率和生物标志物分析

2026-01-280
PRE
Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma

使用BRAF/MEK抑制剂进行诱导治疗与一线使用ipilimumab/nivolumab治疗预后不良的晚期黑色素瘤

2025-10-200
OAAI
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy

在既往接受过ipilimumab为基础治疗方案的患者中,对晚期黑色素瘤患者进行ipilimumab和nivolumab的重新挑战治疗

2025-04-290
PRE
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis

辅助BRAF/MEK与抗PD-1在BRAF突变黑色素瘤中的倾向性评分匹配生存分析

2025-04-150
PRE
Screening for cognitive impairment in routine clinical oncology practice: a pilot study using patient-reported outcome measures and online cognitive testing in melanoma and breast cancer patients

在常规临床肿瘤学实践中筛查认知障碍:一项使用患者报告结局测量和在线认知测试的黑色素瘤和乳腺癌患者试点研究

2025-03-120
OA
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model

荷兰使用卫生经济模型评估BRAF突变型晚期黑色素瘤治疗顺序的成本效益

2025-03-010
PRE
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma

开发决策模型以估计晚期黑色素瘤治疗序列的结果

2025-02-221
OAAI
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry [Eur. J. Cancer 212, 2024, 115056]

辅助免疫疗法在III期和已切除IV期黑色素瘤老年患者中的应用:来自荷兰黑色素瘤治疗登记研究的毒性和无复发生存结果 [Eur. J. Cancer 212, 2024, 115056]

2025-02-010
PRE
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases
CANCER
IF5.1
2024-11-101
OA
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma
2024-11-080
OA